News Archive

Date: 03/01/2013
University of Michigan researchers have discovered that inhibiting a signaling pathway in some of the transplanted cells could prevent the most serious potential complications of the procedure, a conflict between the transplanted cells and the recipient's own tissue called graft-versus-host disease.
Date: 02/26/2013
New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative and that the drug Herceptin, which targets HER2, may have an even greater role for treating breast cancer and preventing its spread.
Date: 02/05/2013
Researchers at the University of Michigan Comprehensive Cancer Center have developed a method that could enhance gene sequencing data.
Date: 01/28/2013
U-M researchers develop method that could enhance gene sequencing dataWritten by Nicole Fawcett
Date: 01/18/2013
Kathleen Cooney, M.D., have been named deputy director for clinical services at the University of Michigan Comprehensive Cancer Center.
Date: 01/14/2013
By looking at the entire DNA from a fibrous tumor, University of Michigan Comprehensive Cancer Center researchers have found a genetic anomaly that provides an important clue to improving how this cancer is diagnosed and treated.
Date: 12/11/2012
Mice without the anti-aging gene had a higher risk of gastrointestinal cancers, according to a study released by the University of Michigan Health System.
Date: 12/11/2012
Written by: Nicole Casal Moore, 734-647-7087, ncmoore@umich.eduNicole Fawcett, 734-764-2220, nfawcett@umich.edu
Date: 12/07/2012
Women undergoing chemotherapy who experience cognitive problems, commonly referred to as 'chemo brain,' displayed alterations in neurocognitive responses prior to undergoing treatment, according to data presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 4-8, 2012.
Date: 12/05/2012
Ponatinib acts against the most resistant types of chronic myeloid leukemia based on the results of a Phase I Trial, reported in the New England Journal of Medicine

Pages